Tranquility Research
Welcome,         Profile    Billing    Logout  
 23 Trials 
106 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Goetz, Matthew P
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
NCT02311933: Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Active, not recruiting
2
81
US
Endoxifen Hydrochloride, Z-Endoxifen HCl, Z-Endoxifen Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Tamoxifen Citrate, Apo-Tamox, Clonoxifen, Dignotamoxi, Ebefen, Emblon, Estroxyn, Fentamox, Gen-Tamoxifen, Genox, ICI 46,474, ICI 46474, ICI-46474, ICI46474, Jenoxifen, Kessar, Ledertam, Lesporene, Nolgen, Noltam, Nolvadex, Nolvadex-D, Nourytam, Novo-Tamoxifen, Novofen, Noxitem, Oestrifen, Oncotam, PMS-Tamoxifen, Soltamox, TAM, Tamax, Tamaxin, Tamifen, Tamizam, Tamofen, Tamoxasta, Tamoxifeni Citras, Zemide
National Cancer Institute (NCI)
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
11/20
02/25
NCT03941730: Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Active, not recruiting
2
5
US
Biopsy, BIOPSY_TYPE, Bx, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Therapeutic Estradiol, 17 Beta-Estradiol, Aquadiol, Climara, Dimenformon, Diogyn, Diogynets, Estrace, ESTRADIOL, Estraldine, Oestradiol, Ovocylin, Progynon, Vagifem
Mayo Clinic, National Cancer Institute (NCI)
Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma
07/26
07/26
BEAUTY, NCT03979508: Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Recruiting
2
200
US
Abemaciclib, LY-2835219, LY2835219, Verzenio, Therapeutic Conventional Surgery
Mayo Clinic, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Breast Fibrocystic Change, Breast Lobular Carcinoma In Situ, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
07/25
07/25
EVANGELINE, NCT05607004: (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Recruiting
2
180
US
(Z)-endoxifen, endoxifen, exemestane, Aromasin, goserelin, Zoladex
Atossa Therapeutics, Inc., InClin
Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
02/26
09/26
NCT06374459: Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Not yet recruiting
1/2
152
US
Zumsemetinib, ATI-450, Capecitabine, Zoledronic acid, Denosumab
Washington University School of Medicine, United States Department of Defense, Aclaris Therapeutics, Inc.
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
06/32
06/32
NCT01327781: Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer

Active, not recruiting
1
62
US
Endoxifen Hydrochloride, Z-Endoxifen HCl, Z-Endoxifen Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Questionnaire Administration
National Cancer Institute (NCI)
HER2/Neu Positive, Recurrent Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
03/17
10/25
NCT05791474: ATI-2231 in Advanced Solid Tumor Malignancies

Withdrawn
1
36
NA
ATI-2231
Washington University School of Medicine, Aclaris Therapeutics, Inc.
Advanced Solid Tumor, Advanced Solid Tumor Malignancies
06/25
06/25
BEAUTY, NCT02022202: Breast Cancer Genome Guided Therapy Study

Active, not recruiting
N/A
140
US
Mayo Clinic
Invasive Breast Cancer
05/14
12/32
NCT00667121: Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Completed
N/A
85
US
citalopram hydrobromide, escitalopram oxalate, gabapentin, sertraline hydrochloride, tamoxifen citrate, venlafaxine, molecular genetic technique, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy
Mayo Clinic, National Cancer Institute (NCI)
Breast Cancer, Depression, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
05/14
05/14
NCT04703244: Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer

Recruiting
N/A
100
US
chemotherapy or endocrine therapy for breast cancer
Mayo Clinic
Breast Cancer, Residual
01/41
01/42
Spigel, David R
MERMAID-2, NCT04642469 / 2020-000612-30: Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

Jan 2024 - Dec 2024: Data from MERMAID-2 trial for NSCLC
Completed
3
30
Europe, Canada, Japan, US, RoW
Durvalumab, Medi4736, Placebo
AstraZeneca
Carcinoma, Non- Small Cell Lung
05/23
01/24
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Completed
3
571
Europe, Canada, US, RoW
NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel
NovoCure Ltd.
Pancreas Adenocarcinoma
10/24
10/24
RAMP-202, NCT04620330 / 2020-004265-39: A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Checkmark Trial initiated for LGSOC and KRAS mutated NSCLC
Dec 2020 - Dec 2020: Trial initiated for LGSOC and KRAS mutated NSCLC
Completed
2
90
Europe, US
avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc.
Non Small Cell Lung Cancer, KRAS Activating Mutation
08/23
12/23
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
NCT03739710 / 2018-001316-29: Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Completed
2
176
Europe, Canada, US, RoW
Docetaxel, Feladilimab, Ipilimumab, GSK4428859A, belrestotug, EOS884448, Dostarlimab, GSK6097608
GlaxoSmithKline, iTeos Belgium SA
Neoplasms
05/24
05/24
NCT05431270: Dose Escalation/Expansion Study of PT199 (an Anti-CD73 MAb) Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Checkmark Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Recruiting
1/2
40
US
PT199, Tislelizumab, Gemcitabine + nab-Paclitaxel, abraxane, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
Phanes Therapeutics, BeiGene
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
12/27
08/28
NCT05271292: Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

Recruiting
1/2
36
US
Chiauranib, CS2164
Chipscreen Biosciences, Ltd.
Small Cell Lung Cancer, Advanced Solid Malignant Tumor
03/25
05/25
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Hourglass Jan 2022 - Dec 2022 : Submission for lung cancer
Hourglass Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer
Checkmark From LIBRETTO-001 trial in RET fusion-positive NSCLC
Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC
Checkmark Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001]
More
Active, not recruiting
1/2
856
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Loxo Oncology, Inc., Eli Lilly and Company
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
02/25
02/26
ELU-FRα-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Terminated
1/2
79
US
ELU001, FA-CDC
Elucida Oncology
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
06/24
06/24
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Completed
1/2
169
US
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Cyteir Therapeutics, Inc.
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
11/24
12/24
BA3011-001, NCT03425279: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients with Sarcoma

Active, not recruiting
1/2
300
US, RoW
CAB-AXL-ADC, PD-1 inhibitor
BioAtla, Inc.
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
01/25
01/25
NCT05887492: Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

Recruiting
1/2
126
US
TNG260, Pembrolizumab, Keytruda
Tango Therapeutics, Inc.
Non Small Cell Lung Cancer, Solid Tumors, Adult, Endometrial Cancer, Pancreatic Cancer, Cervical Cancer, Breast Cancer, Carcinoma of Unknown Primary
01/25
06/25
TNG908-C101, NCT05275478 / 2021-005605-27: Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Active, not recruiting
1/2
192
Europe, US
TNG908
Tango Therapeutics, Inc., Tango Therapeutics, Inc.
Locally Advanced Solid Tumor
04/25
09/25
BA3021-001, NCT03504488 / 2022-000137-17: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Completed
1/2
132
Europe, US, RoW
CAB-ROR2-ADC, BA3021, PD-1 inhibitor
BioAtla, Inc., BioAtla Inc.
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
12/24
12/24
TNG462-C101, NCT05732831: Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Recruiting
1/2
225
Europe, US
TNG462, Pembrolizumab, Keytruda
Tango Therapeutics, Inc.
Locally Advanced Solid Tumor
05/26
09/26
RGX-202-001, NCT03597581: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Recruiting
1
108
US
ompenaclid, RGX-202-01, FOLFIRI, Bevacizumab, FOLFOX regimen
Inspirna, Inc.
Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic
12/24
12/24
ARC-8, NCT04104672: A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Recruiting
1
195
US
AB680, Zimberelimab, AB122, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar
Arcus Biosciences, Inc.
Advanced Pancreatic Cancer
05/27
05/27
LYL797-101, NCT05274451: A Study to Investigate LYL797 in Adults With Solid Tumors

Active, not recruiting
1
100
US
LYL797
Lyell Immunopharma, Inc.
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer
12/25
12/26
MT-6402-001, NCT04795713: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Terminated
1
64
US
MT-6402
Molecular Templates, Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
10/24
10/24
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer

Recruiting
N/A
1050
Europe, US
Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
Razor Genomics, Encore Clinical
Non-Small Cell Lung Cancer
05/27
05/27
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26
Doshi, Ankur
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Recruiting
2
120
Europe, Canada, US
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight or Obesity, CKD, Type 2 Diabetes
11/25
11/25
NCT05569005: Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.

Terminated
N/A
715
Europe, Japan, US, RoW
THS use, Tobacco Heating System 3.0, Cigarette, Smoking Abstinence
Philip Morris Products S.A.
COPD, Smoking, Tobacco Use
09/24
09/24
PI
OASIS, NCT04986995: OpicApone Sleep dISorder

Active, not recruiting
4
22
Europe
Opicapone, BIA 9-1067
Bial - Portela C S.A.
Parkinson Disease
06/23
06/23
ADESOS, NCT05469464 / 2021-006707-15: Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis

Active, not recruiting
2b
210
Europe, US
Orismilast modified release tablets, Placebo
UNION therapeutics
Atopic Dermatitis, Skin Diseases
01/24
02/24
NCT04684914 / 2020-002118-42: HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

Terminated
2
87
Europe, Canada, US
HepTcell, Placebo
Altimmune, Inc., Altimmune, Inc
Hepatitis B, Chronic
03/24
04/24
NCT05686239: A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)

Recruiting
2
234
Europe, US, RoW
RL-007, Placebo
Recognify Life Sciences
Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment, Schizophrenia
06/25
07/25
NCT06040346: Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum

Active, not recruiting
2
60
RoW
Meplazumab for Injection
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
Malaria
08/25
10/25
TRAK-ER, NCT04985266 / 2020-004022-36: A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

Recruiting
2
1100
Europe
Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen, Letrozole, Exemestane, Anastrozole
Royal Marsden NHS Foundation Trust, Pfizer, AstraZeneca, Institute of Cancer Research, United Kingdom, UNICANCER, Gustave Roussy, Cancer Campus, Grand Paris, Invitae Corporation
ER+ Breast Cancer, HER2-negative Breast Cancer
09/27
09/30
NCT05463263: A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Recruiting
1/2
180
Europe, US
STP938
Step Pharma, SAS
Lymphoma, B-Cell, Lymphoma, T-Cell
12/25
12/25
NCT05756322: The Safety and Tolerability of LBS-007 in Patients with Relapsed or Resistant Acute Leukaemias

Recruiting
1/2
90
US, RoW
LBS-007
Lin BioScience, Inc, Lin BioScience Pty Ltd
Relapsed or Resistant Acute Leukaemias
12/25
12/25
NCT04534686: CogXergaming to Promote Physical Activity and Cognitive Function in Frail Older Adults

Completed
N/A
50
US
CogXergaming, Cognitive training, Matter of Balance Training, Conventional training
University of Illinois at Chicago
Frail Older Adults
12/22
03/23
NCT06261216: Association Between Lifetime Physical Activity and Exercise and the Development of Wild-type Transthyretin Amyloid Cardiomyopathy

Recruiting
N/A
252
Europe
Interview
Medical University of Graz, Medical University Innsbruck
Amyloid Cardiomyopathy, Wild Type ATTR Amyloidosis
02/25
02/25
NCT06727240: Safe-Infusion Study

Recruiting
N/A
548
Europe
Intervention
Interlinked AB, Parc Sanitari Sant Joan de Déu, Centro Hospitalar e Universitário de Coimbra, E.P.E.
Intravenous Access, Medical Device
12/24
03/25
Jain, Manish
NCT04467125: Nexplanon Removal: Subcutaneous vs. Topical Lidocaine

Recruiting
4
40
US
Eutectic Lidocaine Prilocaine, EMLA, Subcutaneous Lidocaine
Augusta University
Contraception
05/23
05/23
NCT06229145: A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

Recruiting
4
240
US
Pegloticase, Methotrexate
Amgen
Gout
09/25
05/26
COVER-CoAd, NCT05543642: The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients

Active, not recruiting
4
129
US
Hepatitis A vaccine, Havrix, Diphtheria, pertussis, and tetanus booster vaccine, Boostrix
Oregon Health and Science University
Rheumatic Diseases
01/25
12/25
NCT06015282: The Celljuvant Study: a Phase 3 Immunogenicity and Safety Study of AQIVc Vaccine in Adults Aged 50 Years and Older

Active, not recruiting
3
7741
Europe, Canada, US, RoW
Investigational aQIVc, licensed QIV1, licensed QIV2
Seqirus
Influenza, Human
03/24
01/25
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
TOGETHER-PsA, NCT06588296: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

Recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriatic Arthritis, Obesity
04/26
08/26
GCAptAIN, NCT04930094: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Active, not recruiting
3
354
Europe, Canada, US, RoW
Secukinumab 300 mg, AIN457, Placebo, Placebo Comparator, Secukinumab 150 mg
Novartis Pharmaceuticals
Giant Cell Arteritis (GCA)
04/25
07/27
NCT05658575 / 2019-002717-19: Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Recruiting
2/3
300
Europe, US, RoW
Dapansutrile, OLT1177, Placebo Tablet
Olatec Therapeutics LLC, Olatec Therapeutics LLC
Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
09/25
10/25
CLARITY 2, NCT05122182: Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19

Terminated
2
49
RoW
Candesartan Cilexetil, Repagermanium, DMX-200, Candesartan Placebo, Repagermanium Placebo
University of Sydney, The George Institute for Global Health, India
COVID-19, SARS-CoV2 Infection
08/22
01/23
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
1040
US, RoW
LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492
Eli Lilly and Company
Obesity, Overweight
06/26
09/26
RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Completed
2
491
Europe, Canada, Japan, US, RoW
Peresolimab, Placebo
Eli Lilly and Company
Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases
11/23
01/25
NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Recruiting
2
250
US, RoW
LY3841136, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
06/25
09/25
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US, RoW
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06683508: A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

Recruiting
2
275
US, RoW
LY3549492, Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
09/26
NCT06124807: A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
179
US, RoW
LY3305677, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
01/25
05/25
NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Recruiting
2
120
Europe, Canada, US
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight or Obesity, CKD, Type 2 Diabetes
11/25
11/25
NCT06056258: A Study to Evaluate the Efficacy of VL-NL-02 on Sleep Quality.

Completed
N/A
48
RoW
VL-NL-02, Placebo
Vedic Lifesciences Pvt. Ltd.
Mood and Sleep Quality
04/24
04/24
CORDMILK, NCT03657394: Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries

Recruiting
N/A
3442
RoW
Umbilical cord milking
Nemours Children's Clinic, Sharp HealthCare, Thomas Jefferson University, University of San Diego, St. Louis University, Jawaharlal Nehru Medical College, Daga Memorial Maternity and Children's Hospital, Nagpur, India, Mahatma Gandhi Institue of Medical Sciences, Wardha, India, Karnataka Institue of Medical Sciences, Hubbali, India, Jawaharlal Institute of Postgraduate Medical Education & Research, All India Institute of Medical Sciences, Nagpur, India, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Indira Gandhi Government Medical College & Hospital, Nagpur, India, Pimpri Chinchwad Municipal Corporation's Post-Graduate Institute, Yashwantrao Chavan Memorial Hospital, Pune, India, Government Medical College, Nagpur
Hypoxic-Ischemic Encephalopathy, Birth Asphyxia
06/25
06/25
CORDMILK-PT, NCT06240715: Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries- PreTerm

Recruiting
N/A
800
RoW
Umbilical cord milking, UCM
Nemours Children's Clinic, Thrasher Research Fund, Thomas Jefferson University, Sharp HealthCare, Jawaharlal Nehru Medical College, Daga Memorial Maternity and Children's Hospital, Nagpur, India, Mahatma Gandhi Institute of Medical Sciences, Wardha, India, Indira Gandhi Government Medical College & Hospital, Nagpur, India, Pimpri Chinchwad Municipal Corporation's Post-Graduate Institute, Yashwantrao Chavan Memorial Hospital, Pune, India, Government Medical College, Nagpur, Government Medical College, Chandrapur, India
Preterm, Infant Death
06/26
12/26
CORDMILK-FU, NCT03682042: Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries Developmental Follow Up

Recruiting
N/A
3442
RoW
Umbilical Cord Milking
Nemours Children's Clinic, Sharp HealthCare, Thomas Jefferson University, University of California, San Diego, St. Louis University, KLE Academy of Higher Education and Research (Deemed- to- be-University), Jawaharlal Nehru Medical College (JNMC), Belagavi, India, Government Medical College, Nagpur, Daga Memorial Maternity and Children's Hospital, Nagpur, India, Mahatma Gandhi Institute of Medical Sciences/ Kasturba Hospital, Wardha, India, Karnataka Institute of Medical Sciences, Hubbali, India, All India Institute of Medical Science, Nagpur, India, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Indira Gandhi Government Medical College & Hospital, Nagpur, India, Pimpri Chinchwad Municipal Corporation's Post-Graduate Institute, Yashwantrao Chavan Memorial Hospital, Pune, India
Hypoxic-Ischemic Encephalopathy, Birth Asphyxia
04/27
06/27
Elkhalili, Abdelnaser
NAV3-33, NCT05246280: Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

Terminated
3
196
US
TC99m-tilmanocept, tilmanocept, Lymphoseek
Navidea Biopharmaceuticals
Rheumatoid Arthritis
07/24
07/24
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Checkmark Trial initiation of TOPAZ-1 trial in lupus
Jun 2021 - Jun 2021: Trial initiation of TOPAZ-1 trial in lupus
Recruiting
3
540
Europe, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/26
03/27
Khan, Rabia
NCT05431270: Dose Escalation/Expansion Study of PT199 (an Anti-CD73 MAb) Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Checkmark Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Recruiting
1/2
40
US
PT199, Tislelizumab, Gemcitabine + nab-Paclitaxel, abraxane, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
Phanes Therapeutics, BeiGene
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
12/27
08/28
NCT05074472: A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors

Completed
1/2
35
US
ZB131
ZielBio, Inc.
Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma, Ovarian Serous Adenocarcinoma, Biliary Cancer Metastatic, Ovarian Serous Cystadenocarcinoma
08/23
09/23
STX-001-01, NCT06249048: Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Recruiting
1/2
108
US, RoW
STX-001, Keytruda®, Pembrolizumab
Strand Therapeutics Inc.
Advanced Solid Tumor
05/27
11/28
NCT05500508: Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Terminated
1/2
15
US, RoW
AMXT1501, DFMO, difluoromethyl ornithine monohydrochloride
Aminex Therapeutics, Inc.
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
12/24
12/24
ENBolden-101, NCT04205227: ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors

Active, not recruiting
1/2
137
US, RoW
ENB003, Pembrolizumab, KEYTRUDA®, MK-3475
ENB Therapeutics, Inc, Merck Sharp & Dohme LLC
Cancer, Melanoma, Ovary Cancer, Pancreatic Cancer, Solid Tumor
01/26
03/26
NCT05234853: Safety of PUR001 Monotherapy in Patients With Advanced Solid Tumors

Recruiting
1
23
US
PUR001
Purinomia Biotech, Inc.
Advanced Solid Tumors
12/23
12/23
NCT05539157: Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Active, not recruiting
1
1
US
JCXH-211
Immorna Biotherapeutics, Inc.
Cutaneous Tumor, Malignant Solid Tumor
03/24
05/24
EP31670-01, NCT05488548: Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Recruiting
1
75
US
EP31670, NEO2734
Epigenetix, Inc.
Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
05/25
05/25
SGNB6A-001, NCT04389632: A Study of SGN-B6A in Advanced Solid Tumors

Recruiting
1
824
Europe, US, RoW
sigvotatug vedotin, SGN-B6A, pembrolizumab, Keytruda, cisplatin, carboplatin
Seagen Inc.
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
11/26
02/28
NX-1607-101, NCT05107674: A Study of NX-1607 in Adults With Advanced Malignancies

Recruiting
1
345
Europe, US
NX-1607, Cbl-b Inhibitor, Paclitaxel
Nurix Therapeutics, Inc.
Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
08/26
02/28
NCT04190628: Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

Terminated
1
53
US
ABM-1310, ABM1310, Cobimetinib, Cotellic®
ABM Therapeutics Corporation
Advanced Solid Tumor, BRAF V600 Mutation
04/24
04/24
NCT05831995: Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.

Terminated
1
12
US
ABM-168
ABM Therapeutics Corporation
Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
06/24
06/24
NCT05943743: Hiccups and Obstacles Of E-Learning Among Medical Sudents

Recruiting
N/A
600
RoW
Google form
Bahria University
Covid-19, E-learning, Medical Student
03/25
12/25
Abdellatif, Abdul
NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Recruiting
2
120
Europe, Canada, US
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight or Obesity, CKD, Type 2 Diabetes
11/25
11/25
Christian, Amber
SOSTOS, NCT05090371: A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Recruiting
4
150
Canada, US
Ofatumumab, Disease modifying treatment (DMT)
Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis
12/26
12/26
NCT06003049: A Study to Evaluate Safety and Efficacy of BOTOX in Adults With Moderate COPD

Completed
2
40
US
OnabotulinumtoxinA, BOTOX, Placebo
RMW Testing
COPD
04/24
07/24
EVANGELINE, NCT05607004: (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Recruiting
2
180
US
(Z)-endoxifen, endoxifen, exemestane, Aromasin, goserelin, Zoladex
Atossa Therapeutics, Inc., InClin
Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
02/26
09/26
NCT05431270: Dose Escalation/Expansion Study of PT199 (an Anti-CD73 MAb) Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Checkmark Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Recruiting
1/2
40
US
PT199, Tislelizumab, Gemcitabine + nab-Paclitaxel, abraxane, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
Phanes Therapeutics, BeiGene
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
12/27
08/28
XTX301-01, NCT05684965: XTX301 in Patients with Advanced Solid Tumors

Recruiting
1/2
358
US
XTX301
Xilio Development, Inc.
Advanced Solid Tumor
02/27
02/27
NCT05817045: Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19

Completed
N/A
330
US
RD-X19, Sham
EmitBio Inc.
COVID-19
06/24
06/24
Bates, Deborah
XTX101-01, NCT04896697: Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

Recruiting
1/2
136
US
vilastobart (XTX101), Atezolizumab
Xilio Development, Inc., Hoffmann-La Roche
Advanced Solid Tumor
03/26
03/26
Knecht, John
BRIA-ABC, NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting
3
404
US
SV-BR-1-GM, Part of the Bria-IMT regimen, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
BriaCell Therapeutics Corporation
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
06/25
12/25
VAYHIT2, NCT05653219: A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

Recruiting
3
150
Europe, Japan, US, RoW
Ianalumab, VAY736, Eltrombopag, ETB115, Placebo
Novartis Pharmaceuticals
Primary Immune Thrombocytopenia
08/25
05/28
NCT05085002 / 2021-005238-40: A Study of Lerociclib in Participants With Advanced Breast Cancer

Terminated
2
100
Europe, US, RoW
Lerociclib + Letrozole or Fulvestrant
EQRx, Inc.
Advanced Breast Cancer
11/23
11/23
VERSATILE-002, NCT04260126: Study of PDS0101 and Pembrolizumab Combination I/O in Subjects with HPV16 + Recurrent And/or Metastatic HNSCC

Checkmark Data from VERSATILE-002 clinical trial in combination with PDS0101 for metastatic head and neck cancer at MHNCS 2022
Feb 2022 - Feb 2022: Data from VERSATILE-002 clinical trial in combination with PDS0101 for metastatic head and neck cancer at MHNCS 2022
Active, not recruiting
2
95
Europe, US
Pembrolizumab (KEYTRUDA®) and PDS0101
PDS Biotechnology Corp., Merck Sharp & Dohme LLC
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
06/25
06/25
EVANGELINE, NCT05607004: (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Recruiting
2
180
US
(Z)-endoxifen, endoxifen, exemestane, Aromasin, goserelin, Zoladex
Atossa Therapeutics, Inc., InClin
Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
02/26
09/26
NCT05431270: Dose Escalation/Expansion Study of PT199 (an Anti-CD73 MAb) Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Checkmark Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Initial results from the TROPION-PanTumor01 trial in HR+ve, HER2 low or HER2-ve metastatic breast cancer at SABCS 2022
Recruiting
1/2
40
US
PT199, Tislelizumab, Gemcitabine + nab-Paclitaxel, abraxane, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
Phanes Therapeutics, BeiGene
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
12/27
08/28
BRI-ROL-001, NCT03328026: Combination Study of SV-BR-1-GM With Retifanlimab

Checkmark In combination with Bria-IMT for advanced breast cancer
Sep 2019 - Sep 2019: In combination with Bria-IMT for advanced breast cancer
Checkmark Safety data in combination with Bria-IMT
Dec 2018 - Dec 2018: Safety data in combination with Bria-IMT
Checkmark Anticipated efficiency data in combination with Bria-IMT
More
Enrolling by invitation
1/2
36
US
SV-BR-1-GM, Low dose cyclophosphamide, Cytoxan, Interferon Inoculation, retifanlimab, INCMGA00012
BriaCell Therapeutics Corporation, LumaBridge
Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic
06/24
06/24
 

Download Options